版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)
文檔簡介
NCCNClinicalPracticeGuidelinesinOncologyNCCNGuidelines?)AmpullaryAdenocarcinomarsionMarchVersion1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadex*MargaretA.Tempero,MD/Chair??UCSFHelenDillerFamilyComprehensiveCancerCenternternter**StephenW.Behrman,MD/Co-Lead?TheUniversityofTennesseeeCenter**E.GabrielaChiorean,MD/Co-Lead?FredHutchinsonCancerResearchCenter/SeattleCancerCareAllianceyofMichiganRogelyofMichiganRogelCancerCenter**AlB.BensonIII,MD?RobertH.LurieComprehensiveCancerCenterofNorthwesternUniversityngramCancerCenterVincentChung,MDngramCancerCenterVincentChung,MD?yofHopeNationalMedicalCenter**BrianCzito,MD§DukeCancerInstituteofColoradoCancerCenterChiaroofColoradoCancerCenterMaryDillhoff,MD,MS?TheOhioStateUniversityComprehensiveCancerCenter-JamesCancerHospitalandSoloveResearchInstituteTimothyR.Donahue,MD?UCLAJonssonComprehensiveCancerCenterEfratDotan,MD?FoxChaseCancerCenterCristinaR.Ferrone,MD?MassachusettsGeneralHospitalCancerCenteresPanelDisclosuresChristosFountzilas,MD?RoswellParkComprehensiveCancerCenterJeffreyHardacre,MD?CaseComprehensiveCancerCenter/UniversityHospitalsSeidmanCancerCenterandClevelandClinicTaussigCancerInstitutemanCancerCenteratBarnesmanCancerCenteratBarnesJewishHospitaltonUniversitySchoolofMedicineEdwardJ.Kim,MD,PhD?UCDavisComprehensiveCancerCenterfettCancerfettCancerCenterAndrewH.Ko,MD?UCSFHelenDillerFamilyComprehensiveCancerCenternterSmilowCancerHospitalnterSmilowCancerHospital**NoelleLoConte,MD?UniversityofWisconsinCarboneCancerCenter**AndrewM.Lowy,MD?UCSanDiegoMooresCancerCenterMoravekPancreaticCancerActionNetworkPatricioM.Polanco,MD?UTSouthwesternSimmonsComprehensiveCancerCenterONealComprehensiveCancerCenterONealComprehensiveCancerCenteratUABMarshaReyngold,MD,PhD§MemorialSloanKetteringCancerCenterrInstituteattherInstituteatthefUtah**JeanneShen,MD≠StanfordCancerInstituteMarkJ.Truty,MD,MS?MayoClinicCancerCenterAbramsonCancerCenterattheAbramsonCancerCenteratthensylvaniaandWomensnMWolpinandWomensenterghRNBSghRNBSenPhDUCSFHelenDillerFamilyComprehensiveCancerCenterAmolK.Narang,MD§TheSidneyKimmelComprehensiveosticgyosticgy¤Gastroenterology?Hematology/Hematologyoncology?Medicaloncology≠Pathology¥Patientadvocacy§Radiotherapy/Radiationoncology?Surgery/Surgicaloncology*Discussionsectionwritingcommittee**Development/writingsubcommittee**JorgeObando,MD¤stituteVersion1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AmpullaryAdenocarcinomaPanelMembersofAmpullaryNeoplasmAMPyAdenomaAMPAdenocarcinoma(AMP-3)LocalizedDisease(AMP-4)PostoperativeAdjuvantTherapy(AMP-5)seaseAmpullaryAdenocarcinomaPanelMembersofAmpullaryNeoplasmAMPyAdenomaAMPAdenocarcinoma(AMP-3)LocalizedDisease(AMP-4)PostoperativeAdjuvantTherapy(AMP-5)seaseAMPssionAMPPrinciplesofDiagnosis,Imaging,andStaging(AMP-A)PancreaticCancerRadiologyReportingTemplate(AMP-A,5of8)PrinciplesofStentManagement(AMP-B)PrinciplesofSurgicalTechnique(AMP-C)PathologicAnalysis:SpecimenOrientation,HistologicSections,andReporting(AMP-D)PrinciplesofSystemicTherapy(AMP-E)PrinciplesofRadiationTherapy(AMP-F)PrinciplesofPalliationandSupportiveCare(AMP-G)ocarcinomadexdNCCNCategoriesofPreference:Allrecommendationsareconsideredappropriate.SeeNCCNCategoriesofPreference.TheNCCNGuidelinesareastatementofevidenceandconsensusoftheauthorsregardingtheirviewsofcurrentlyacceptedapproachestotreatmentAnyclinicianseekingtoapplyorconsulttheNCCNGuidelinesisexpectedtouseindependentmedicaljudgmentinthecontextofindividualstancestodetermineanypatientscareortreatmentTheNationalComprehensiveCancerNetworkNCCNmakesnorepresentationsorwarrantiesofanykindregardingtheircontentuseorapplicationanddisclaimsanyresponsibilityfortheirapplicationoruseinanywayTheNCCNbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.?2022.Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexCLINICALWORKUPTREATMENTPRESENTATIONcionymprotocolCTandpelvisandpelvisa?Esophagogastroduodenoscopy(EGD)±endoscopicultrasound(EUS)withbiopsy?ColonoscopyifnotpreviouslyperformedaccordingtoestablishedguidelinesHigh-gradedysplasiaSeeAmpullaryAdenoma(AMP-2)denocarcinomaAdenocarcinoma(AMP-3)aSeePrinciplesofDiagnosis,Imaging,andStaging(AMP-A).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AMP-1PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexCLINICALPRESENTATIONTREATMENTmpullaryNegativemarginsampullectomyampullectomybNegativemargins Pancreatoduodenectomy PancreatoduodenectomybtomybampullectomyampullectomybNegativemarginssrPancreatoduodenectomybtomybEndoscopicsurveillanceillanceEndoscopicsurveillanceillancebSeePrinciplesofSurgicalTechnique(AMP-C).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AMP-2rfunctionstbaselineACEA?ConsiderERCP/PTCasclinicallyindicated?Considerestingforinheritedmutationsc?MultidisciplinaryondPrintedbyMinTangon3/14/20227:27:24AM.ForpersonalrfunctionstbaselineACEA?ConsiderERCP/PTCasclinicallyindicated?Considerestingforinheritedmutationsc?MultidisciplinaryondocarcinomadexCLINICALPRESENTATIONAdenocarcinomaWORKUP?CTchest,andpancreasprotocolCTofMetastaticTREATMENT?ConsiderMRIforindeterminateliverlesionsasclinicallyindicated?HistologicsubtypepancreatobiliaryversusintestinalifpossibletepreferredeonsidermoleculartepreferredeonsidermolecularprofilingfoftumortissueasallyindicatedaSeePrinciplesofDiagnosis,Imaging,andStaging(AMP-A).cGenetictestingforinheritedmutationsisrecommendedforanypatientwithconfirmedampullarycancer,usingcomprehensivegenepanelsforhereditarycancersyndromes.Geneticcounselingisrecommendedforpatientswhotestpositiveforapathogenicmutation(ATM,BRCA1,BRCA2,CDKN2A,MLH1,MSH2,MSH6,PALB2,PMS2,STK11,andTP53)orforpatientswithapositivefamilyhistoryofcancer,especiallypancreatic/ampullarycancer,regardlessofmutationstatus.SeeNCCNGuidelinesforGenetic/FamilialHighRiskAssessment:Breast,Ovarian,andPancreatic.dMultidisciplinaryreviewshouldconsiderinvolvingexpertisefromdiagnosticimaging,interventionalendoscopy,medicaloncology,radiationoncology,surgery,pathology,geriatricmedicine,geneticcounseling,andpalliativecare(seePrinciplesofPalliationandSupportiveCare[AMP-G]).Considerconsultationwitharegistereddietitian.SeeNCCNGuidelinesforOlderAdultOncologyandNCCNGuidelinesforPalliativeCare.eCorebiopsyisrecommended,ifpossible,toobtainadequatetissueforpossibleancillarystudies.fTumor/somaticmolecularprofilingisrecommendedforpatientswithlocallyadvanced/metastaticdiseasewhoarecandidatesforanti-cancertherapytoidentifyuncommonmutations.Considerspecificallytestingforpotentiallyactionablesomaticfindingsincluding,butnotlimitedto:fusions(ALK,NRG1,NTRK,ROS1,FGFR2,RET),mutations(BRAF,BRCA1/2,KRAS,PALB2),amplifications(HER2),microsatelliteinstability(MSI)and/ormismatchrepair(MMR)deficiency.Testingontumortissueispreferred;however,cell-freeDNAtestingcanbeconsiderediftumortissuetestingisnotfeasible.SeeDiscussion.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-3Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.icularlyinighriskpatientsiPrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.icularlyinighriskpatientsiocarcinomadexCLINICALPRESENTATIONTREATMENTProceedtosurgerywithoutneoadjuvanttherapy)SurgerygProceedtosurgerywithoutroradiationhjoradiationhjkstentlifstentlifclinicallyTorMRIResectableSurgerygUnresectablePeMetastaticDiseaseAMPgSeePrinciplesofSurgicalTechnique(AMP-C)andPathologicAnalysis:SpecimenOrientation,HistologicSections,andReporting(AMP-D).hSeePrinciplesofSystemicTherapy(AMP-E).iHigh-riskfeaturesincludeimagingfindings,markedlyelevatedCA19-9,markedlyelevatedcarcinoembryonicantigen(CEA),largeprimarytumors,largeregionallymphnodes,excessiveweightloss,andextremepain.jThereislimitedevidencetorecommendspecificneoadjuvantregimensoff-study,andpracticesvarywithregardtotheuseofchemotherapyandchemoradiation.kSeePrinciplesofRadiationTherapy(AMP-F).lSeePrinciplesofStentManagement(AMP-B).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-4Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.kSeePrinciplesofRadiationTherapy(AMP-F).mInitiationofadjuvantsystemictherapyisrecommendedwithin12weeksofsurgeryifthepatientismedicallyfit.TheoptimaldurationoftreatmentiskSeePrinciplesofRadiationTherapy(AMP-F).mInitiationofadjuvantsystemictherapyisrecommendedwithin12weeksofsurgeryifthepatientismedicallyfit.Theoptimaldurationoftreatmentis4to6months.ocarcinomadexPOSTOPERATIVEADJUVANTTREATMENTTREATMENTSURVEILLANCEyobservationSystemictherapyh,m±StageIobservationSystemictherapyh,m±observationStageIIchemoradiationh,k,mobservationStageIIIStageIIISystemictherapyh,m±StageIVSeeMetastaticDisease(AMP-6)Surveillanceevery3-6monthsfor2years,thenevery6-12monthsion?Historyandphysicalexamination(H&P)?ChestCTandCTorMRIoftrastaabdomenandpelvistrastahSeePrinciplesofSystemicTherapy(AMP-E).aSeePrinciplesofhSeePrinciplesofSystemicTherapy(AMP-E).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-5Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexMETASTATICDISEASETREATMENTtictestingforinheritedmutations,ifnotlecularproilingoftumortissue,ifnotGoodPSnPoorPStionhktionhkcctherapyhllowedllowedbyrpalliativeSystemicSystemictherapyhfollowedbylocal-directedtherapytoliverorlungtastasesforselectpatientswithligometastaticdiseaseandresponsetablediseasetosystemictherapyprogressionSeeAMP-7PalliativeandbestsupportivecareoystemictherapyhTargetedtherapyhbasedonmolecularproilingfasclinicallyindicatedliativeliativeRTkdGenetictestingforinheritedmutationsisrecommendedforanypatientwithconfirmedampullarycancer,usingcomprehensivegenepanelsforhereditarycancersyndromes.Geneticcounselingisrecommendedforpatientswhotestpositiveforapathogenicmutation(ATM,BRCA1,BRCA2,CDKN2A,MLH1,MSH2,MSH6,PALB2,PMS2,STK11,andTP53)orforpatientswithapositivefamilyhistoryofcancer,especiallypancreatic/ampullarycancer,regardlessofmutationstatus.SeeNCCNGuidelinesforGenetic/FamilialHighRiskAssessment:Breast,Ovarian,andPancreatic.fTumor/somaticmolecularprofilingisrecommendedforpatientswithlocallyadvanced/metastaticdiseasewhoarecandidatesforanti-cancertherapytoidentifyuncommonmutations.Considerspecificallytestingforpotentiallyactionablesomaticfindingsincluding,butnotlimitedto:fusions(ALK,NRG1,NTRK,ROS1,FGFR2,RET),mutations(BRAF,BRCA1/2,KRAS,PALB2),amplifications(HER2),microsatelliteinstability(MSI)and/ormismatchrepair(MMR)deficiency.Testingontumortissueispreferred;however,cell-freeDNAtestingcanbeconsiderediftumortissuetestingisnotfeasible.SeeDiscussion.hSeePrinciplesofSystemicTherapy(AMP-E).kSeePrinciplesofRadiationTherapy(AMP-F).nDefinedasECOG0–1,withgoodbiliarydrainageandadequatenutritionalintake.oSeePrinciplesofPalliationandSupportiveCare(AMP-G).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-6Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRightsReserved.ocarcinomadexDISEASEPROGRESSIONSUBSEQUENTTHERAPYpmolecularproiling,fasclinicallymolecularproiling,fasclinicallyindicatedSystemicSystemictherapyhorpossiblytargetedtherapyf,hbasedonPalliativeRTkforseverepainrefractorytoanalgesictherapyPalliativerialPalliativeandbestsupportivecareoystemictherapyhTargetedtherapyf,hbasedonmolecularproiling,fasclinicallyindicatediativeiativeRTkfTumorsomaticmolecularprofilingisrecommendedforpatientswithlocallyadvancedmetastaticdiseasewhoarecandidatesforanti-cancertherapytoidentifyuncommonmutationsConsiderspecificallytestingforpotentiallyactionablesomaticfindingsincludingbutnotlimitedto:fusions(ALK,NRG1,onsBRAFBRCAKRASPALBamplifications(HER2),microsatelliteinstability(MSI)and/ormismatchrepairrredhowevercellfreeDNAtestingcanbeconsiderediftumortissuetestingisnotfeasible.SeeDiscussion.hSeePrinciplesofSystemicTherapy(AMP-E).kSeePrinciplesofRadiationTherapy(AMP-F).nDefinedasECOG0–1,withgoodbiliarydrainageandadequatenutritionalintake.oSeePrinciplesofPalliationandSupportiveCare(AMP-G).pSerialimagingasindicatedtoassessdiseaseresponse.SeePrinciplesofDiagnosis,Imaging,andStaging(AMP-A).Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.AMP-7Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.AMP-AOF8institutionalpreferencesMultiplanarreconstructionispreferredasitallowsprecisevisualizationoftherelationshipoftheprimarytumorPrintedbyMinTangon3/14/20227:27:24AM.ForAMP-AOF8institutionalpreferencesMultiplanarreconstructionispreferredasitallowsprecisevisualizationoftherelationshipoftheprimarytumorocarcinomadexPRINCIPLESOFDIAGNOSIS,IMAGING,ANDSTAGINGDecisionsaboutdiagnosticmanagementandresectabilityshouldinvolvemultidisciplinaryconsultationatahigh-volumecenterwithreferencetoappropriatehighqualityimagingstudiestoevaluatetheextentofdiseaseResectionsshouldbedoneatinstitutionsthatperformalargenumberatleastofpancreaticresectionsand/orendoscopicandsurgicalampullectomyannually.Highqualitydedicatedimagingoftheampullaryregionshouldbeperformedatpresentation(evenifstandardCTimagingisalreadyavailablepreferablywithinweeksofsurgeryandfollowingneoadjuvanttreatmenttoprovideadequatestagingandassessmentofresectabilitystatus.Imagingshouldbedonepriortostenting,whenpossible.?ImagingshouldincludededicatedpancreaticCTofabdomen(preferred)orMRIwithcontrast.pMultidetectorcomputedtomography(MDCT)angiography,performedbyacquiringthin,preferablysub-millimeter,axialsectionsusingaimagingtoolfordedicatedpancreaticimaging.aScancoveragecanbeextendedtocoverthechestandpelvisforcompletestagingasimagingtoolfordedicatedpancreaticimaging.aScancoveragecanbeextendedtocoverthechestandpelvisforcompletestagingaspertothemesentericvasculatureaswellasdetectionofsubcentimetermetastaticdeposits.SeeMDCTPancreaticAdenocarcinomaProtocol,PANC-A(3of8).pMRIismostcommonlyusedasaproblem-solvingtool,particularlyforcharacterizationofCT-indeterminateliverlesionsorwhencontrast-enhancedCTcannotbeobtained(asincaseswithsevereallergytoiodinatedintravenouscontrastmaterial).ThispreferenceforusingMDCTasthemainimagingtoolinmanyhospitalsandimagingcentersismainlyduetothehighercostandlackofwidespreadavailabilityofMRIcomparedtoCT.SeeMRIPancreaticAdenocarcinomaProtocol,AMP-A(4of8).?Thedecisionregardingresectabilitystatusshouldbemadebyconsensusatmultidisciplinarymeetings/discussionsfollowingthecompleteassessmentandreportingofallimagingcriteriaessentialforoptimalstaging,whichwillimprovethedecision-makingprocess.aacquisitionofcompleteassessmentandreportingofallimagingcriteriaessentialforoptimalstaging,whichwillimprovethedecision-makingprocess.aSeePancreaticCancerRadiologyReportingTemplateAMPAofThistemplatecanalsobeusedforampullarytumors.ancisIRChariSTetalPancreaticductaladenocarcinomaradiologyreportingtemplateconsensusstatementoftheSocietyofAbdominalRadiologyandtheAmericanPancreaticAssociationRadiology260.Note:Allrecommendationsarecategory2Aunlessotherwiseindicated.ClinicalTrials:NCCNbelievesthatthebestmanagementofanypatientwithcancerisinaclinicaltrial.Participationinclinicaltrialsisespeciallyencouraged.Version1.2022,03/09/22?2022NationalComprehensiveCancerNetwork(NCCN),Allrightsreserved.NCCNGuidelinesandthisillustrationmaynotbereproducedinanyformwithouttheexpresswrittenpermissionofNCCN.PrintedbyMinTangon3/14/20227:27:24AM.Forpersonaluseonly.Notapprovedfordistribution.Copyright?2022NationalComprehensiveCancerNetwork,Inc.,AllRights
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 小班音樂教育的實踐與探索計劃
- 爐邊產(chǎn)品銷售合同三篇
- 讓每個孩子在班級中閃耀光芒計劃
- 太陽能電池組件相關(guān)行業(yè)投資規(guī)劃報告范本
- 健康保健服務(wù)相關(guān)行業(yè)投資方案
- 農(nóng)業(yè)運輸機械行業(yè)相關(guān)投資計劃提議范本
- 《信陽技工學(xué)?!氛n件
- xx鄉(xiāng)村級網(wǎng)格化管理方案
- 《保健品科普收單》課件
- 【培訓(xùn)課件】貨品分析-店長培訓(xùn)
- GB/T 27800-2011靜密封橡膠制品使用壽命的快速預(yù)測方法
- 醫(yī)生、護士工作服技術(shù)參數(shù)要求
- GB 29518-2013柴油發(fā)動機氮氧化物還原劑尿素水溶液(AUS 32)
- 《經(jīng)濟學(xué)基礎(chǔ)》試題庫(附答案)
- 中學(xué)生法制教育主題班會課件《預(yù)防未成年人犯罪》
- 雙氧水工藝培訓(xùn)課件
- 醫(yī)師臨床三基訓(xùn)練綜合試卷
- 激光雷達測風(fēng)技術(shù)完整版課件
- 2023年江蘇省環(huán)保集團有限公司校園招聘筆試題庫及答案解析
- 繪畫心理測試與治療課件
- 國家開放大學(xué)《公共政策概論》形考任務(wù)1參考答案
評論
0/150
提交評論